A
Antonio Craxì
Researcher at University of Palermo
Publications - 699
Citations - 44773
Antonio Craxì is an academic researcher from University of Palermo. The author has contributed to research in topics: Hepatitis C & Cirrhosis. The author has an hindex of 86, co-authored 659 publications receiving 39463 citations. Previous affiliations of Antonio Craxì include University of Pavia & University of Paris-Sud.
Papers
More filters
Journal ArticleDOI
Hepatitis C in the elderly: A multicentre cross-sectional study by the Italian Association for the Study of the Liver
Annagiulia Gramenzi,Fabio Conti,Calogero Cammà,Antonio Grieco,Antonino Picciotto,Caterina Furlan,Domenico Romagno,Paolo Costa,Maria Rendina,Fausto Ancarani,Maria Chiaramonte,Gabriella Verucchi,Antonio Craxì,Mauro Bernardi,Pietro Andreone +14 more
TL;DR: Elderly hepatitis C virus patients referred to Italian specialty clinics have advanced and underestimated liver disease, and are progressively understudied in parallel with increasing age.
Journal ArticleDOI
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel.
Mauro Viganò,Carlo Federico Perno,Antonio Craxì,Alessio Aghemo,Alfredo Alberti,Pietro Andreone,Massimo Andreoni,Stefano Bonora,Maurizia Rossana Brunetto,Raffaele Bruno,Savino Bruno,Vincenza Calvaruso,Nicola Caporaso,Francesca Ceccherini-Silberstein,Valeria Cento,Alessia Ciancio,Piero Colombatto,Elisabetta Degasperi,Vito Di Marco,Giovanni Di Perri,Gianpiero D'Offizi,Stefano Fagiuoli,Carlo Ferrari,Giovanni Battista Gaeta,Adriano M. Pellicelli,Salvatore Petta,Sara Piovesan,Massimo Puoti,Giovanni Raimondo,Francesco Paolo Russo,Gloria Taliani,Ugo Trama,Erica Villa,Anna Linda Zignego +33 more
TL;DR: To assess the Italian treatment experience with DAAs and to respond to unmet needs in treatment optimization of antiviral therapy in specific settings of CHC patients, a group of Italian experts met in Stresa in February 2017.
Journal ArticleDOI
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.
Pietro Lampertico,Maurizia Rossana Brunetto,Antonio Craxì,Giovanni Battista Gaeta,Mario Rizzetto,Antonella Rozzi,Massimo Colombo +6 more
TL;DR: Addition of peginterferon alfa‐2a to ongoing NA therapy significantly decreased HBsAg levels in HBeAg‐negative patients with genotype D infection, with week 12 levels significantly associated with response.
Journal ArticleDOI
PNPLA3 and TLL-1 Polymorphisms as Potential Predictors of Disease Severity in Patients With COVID-19
Stefania Grimaudo,Emanuele Amodio,Rosaria Maria Pipitone,Carmelo Massimo Maida,Stefano Pizzo,Tullio Prestileo,Fabio Tramuto,Davide Stefano Sardina,Francesco Vitale,Alessandra Casuccio,Antonio Craxì +10 more
TL;DR: In this paper, the authors used whole nucleic acids extracted from nasopharyngeal swabs to identify host gene polymorphisms in genes involved in infection and reinfection, inflammation, or immune stimulation.
Journal ArticleDOI
Liver‐related and extrahepatic events in patients with non‐alcoholic fatty liver disease: a retrospective competing risks analysis
Grazia Pennisi,Marco Enea,Manuel Romero-Gómez,Mauro Viganò,Elisabetta Bugianesi,Vincent Wai-Sun Wong,Anna Ludovica Fracanzani,Giada Sebastiani,Jérôme Boursier,Annalisa Berzigotti,Mohammed Eslam,Javier Ampuero,Amine Benmassaoud,C. La Mantia,Yuly P. Mendoza,Jacob George,Antonio Craxì,Calogero Cammà,Victor de Ledinghen,Salvatore Petta +19 more
TL;DR: A large cohort of biopsy‐proven NAFLD stratified according to baseline severity of fibrosis found that fibrotic non‐alcoholic steatohepatitis has a high competitive risk of liver‐related events and extrahepatic events.